Tobramycin inhalation therapy is an effective therapy for cystic fibrosis as well as severe bronchiectasis that is colonized with Pseudomonas aeruginosa. The mechanism responsible for the efficacy of tobramycin in the treatment of severe chronic infectious diseases has not been elucidated. We demonstrate that high-dose tobramycin decreases MUC5AC gene expression and protein production in NCI-H292 cell stimulated with lipopolysaccharide of P. aeruginosa. MUC5AC protein of NCI-H292 cell stimulated by lipopolysaccharide was analyzed by an enzyme-linked immunosorbent assay and MUC5AC expression at the mRNA level was analyzed by RT-PCR. Westernblot was performed to examine a potential role for the signaling molecules upstream of NFB.
Introduction
Chronic respiratory infectious diseases are difficult to treat, especially when the bronchial tissue is colonized and infected with Pseudomonas aeruginosa (［Eitzgerald et al., 1996］, ［Gibson et al., 2003］, ［Li et al., 1997］) . The intermittent administration of inhaled tobramycin is an effective treatment for cystic fibrosis (CF) patients; tobramycin treatment leads to improved pulmonary function, a decreased density of P. aeruginosa in sputum, and a decreased risk of hospitalization (［Gibson et al., 2003］, ［Lee et al., 2004］, ［Ramsey et al., 1999］, ［Ratjen et al., 2001］) . Some authors reported that tobramycin inhalation therapy is also clinically effective for severe, non-cystic fibrosis bronchiectasis colonized with P. aeruginosa (［Bilon et al., 2006］, ［Dal Nergo et al., 2008］, ［Dohrman et al., 1998］, ［Scheinberg et al., 2005］) . It has been reported that tobramycin is effective because it can decrease the bacterial density in sputum due to its ability to directly reach the infectious source at high concentrations, even if the lung tissue is destroyed; another report indicates that tobramycin can suppress the pathogenesis of P. aeruginosa, but the details of the mechanism have not been elucidated (［Geller et al., 2002］, ［Husson et al., 2005］) .
Mucus secretion, which protects the host's mucosal surfaces against pathogens, is a component of the innate immunity system. However, mucus hyperproduction can be a 6 risk factor for pathogenesis because excessive mucus secretion causes airway obstruction, impairment of gas exchange, and obstructive pneumonia. The major macromolecular component of mucus is mucin protein. The MUC5AC gene encodes the major core protein of mucin secreted from the airway surface epithelium (［Davies et al., 1999 ］ , ［ Gendler et al., 1995 ］ , ［ Hovenberg et al., 1996 . Bacterial infection, especially P. aeruginosa, plays an important role in chronic respiratory infection. P. aeruginosa and lipopolysaccharide (LPS) stimulate mucin production (［Li et al., 1997］, ［Dohrman et al., 1998］, ［Kaneko et al., 2003］, ［Tamaoki et al., 1997］, ［Yanagihara et al., 2001 . Toll-like receptors (TLRs) play a key role in sensing microbial components and inducing innate immune responses, and LPS-induced dimerization of TLR4 is required for activation of downstream signaling pathways (［Lee et al., 2004］, ［Medzhitov et al., 2001］) . Stimulation of TLR4 by LPS activates both myeloid differential factor 88 (MyD88) and Toll/interleukin-1 receptor domain-containing adaptor protein inducing interferon beta (TRIF)-dependent signaling pathways leading to activation of mitogen-activated protein (MAP) kinase and nuclear factor kappaB (NFB) (［Kawai et al., 2005］, ［Takeyama et al., 1999］) . For patients with chronic respiratory infectious disease, the control of mucus overproduction is considered beneficial for decreasing the disease severity and improving quality of life.
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In the present study, to confirm the clinical effect of high-dose tobramycin inhalation therapy, we investigated whether high-dose tobramycin can inhibit LPS-induced mucin secretion from airway epithelial cells activated to produce the mucin core protein, MUC5AC.
Materials and methods

2.1.
Materials. We purchased LPS of P. aeruginosa serotype 10, tobramycin, and dexamethasone from Sigma (Tokyo, Japan) and the RPMI 1640 medium, streptomycin. The cells were grown at 37°C with 5% CO 2 in fully humidified air and were subcultured twice weekly. The cells were seeded in a 12-well plate at 5 × 10 5 cells/well. When confluent, the cells were incubated in RPMI 1640 medium containing 0.5% fetal bovine serum for 24 h. The cells then were rinsed with serum-free RPMI 1640 medium and exposed to LPS. We used P. aeruginosa LPS for stimulating the cell line to exclude the bactericidal effect of tobramycin. For inhibition studies, cells were pretreated with tobramycin 30min before exposure to LPS. For controls, the cells were incubated with medium alone.
2.3.
RNA extraction and reverse transcription PCR. Total RNA was prepared by using QuickGene RNA cultured cell kit S (Fujifilm, Tokyo, Japan). After contaminating DNA was removed with DNase (Message Clean kit; GenHunter, Nashville, TN), cDNA was constructed from 1 µg total RNA by using the 9 SuperScript III CellDirect cDNA Synthesis Kit (Invitrogen) according to the manufacturer's instructions. Sequences for the MUC5AC primers are: ATC ACC GAA GGC TGC TTC TGT C (sense) and GTT GAT GCT GCA CAC TGT CCA G (antisense) (Imamura et al., 2004) . PCR was performed in a total volume of 20 μl containing 5 μl cDNA template, 4 μl LightCycler Taqman Master mixture (Roche Diagnostics, Basel, Switzerland), 0.2 μM Taqman probe, and 0.5 μM each primer.
Thermal cycling was performed with an initial hold for 10 min at 95°C, followed by 30 cycles of 10 s at 95°C, 10 s at 64°C. Data was analyzed by LightCycler Software (v3.5) in the F1 mode with a fit point calculation method. Human porphobilinogen deaminase controls were used to standardize the quantification of RNA samples. We performed four times experiments.
2.4.
ELISA. The NCI-H292 cells were incubated in a 12-well plate, and the level of MUC5AC protein was measured by an enzyme-linked immunosorbent assay (ELISA) (Kaneko et al., 2003) . Briefly, the cells were washed with phosphate buffered saline (PBS), exposed to trypsin, and centrifuged at 600 × g at 4°C for 5 min to form pellets. The pellets were resuspended in lysis buffer (20 mM Tris-HCl [pH 8.0], 133 mM NaCl, 1% NP-40, 10% glycerol). The preparation then was cleared by centrifugation, and the supernatant was saved as a whole-cell lysate.
Protein concentrations in the supernatant were measured, and equal amounts of total protein were incubated at 40°C in a 96-well plate until dry. The plates then were washed three times with PBS, blocked with 2% bovine serum albumin for 1 h at room temperature, and incubated with MUC5AC antibody diluted 1:100 in PBS containing 0.05% Tween 20 for 1 h. The wells were washed three times with 400 µl PBS, HRP-conjugated anti-goat immunoglobulin G diluted 1:10,000 in PBS containing 0.05% Tween 20 was dispensed into each well for 1 h. The plates were washed three times with 400 µl PBS. Color was developed with 3,3′,5,5′-tetramethylbenzidine-peroxidase solution, and the reaction was stopped with 1 N H 2 SO 4 . The absorbance was read at 450 nm. We performed four times experiments.
2.5.
Western blot analysis and antibodies. Cells 
Statistical analysis.
All data were expressed as the mean and standard deviation (SD). Differences were examined for statistical significance by using the one-way analysis of variance for comparisons involving more than two groups and the Student's t test for comparisons between two groups. P values less than 0.05 were considered statistically significant.
Results
3.1.
High-dose tobramycin inhibits MUC5AC protein production and mRNA expression induced by LPS in NCI-H292 cells. As shown in Fig. 1A , the MUC5AC protein production induced by LPS increased time dependently, and 13 MUC5AC production was maximal at 24h after LPS stimulation, so we performed the MUC5AC inhibition assay at 24 h after LPS stimulation. To determine the appropriate dosage of tobramycin for the inhibition of MUC5AC protein expression, we treated cells with tobramycin (1 to 2000 µg/ml). We used 10µg/ml dexamethasone as a positive control. As shown in Figure 1B , 500 µg/ml tobramycin was needed at least to decrease the MUC5AC protein production. We also performed the inhibition study of mRNA 12h after LPS stimulation because the level of mRNA expression was maximal 12h after LPS stimulation (data not shown).
As shown in Figure 2 , 500 μg/ml tobramycin also reduced MUC5AC expression at the mRNA level. Tobramycin had no inhibitory effect on the basal expression of MUC5AC (data not shown). Furthermore, tobramycin exposure did not significantly alter cell numbers and increase the lactate dehydrogenase (LDH) level of the supernatant.
High-dose tobramycin inhibits NFB activation induced by LPS in
NCI-H292 cells. The activation of NFB is an important factor in causing inflammation in bronchial epithelial cells. To determine whether tobramycin down-regulates NFB activity, we performed an assay of transcription factors. The activity levels of NFB p50 and p65 were increased by LPS stimulation in a 14 time-dependent manner, and they reached a maximum level 60 min after LPS stimulation ( Figure 3A-i and ii) , so we performed the inhibition assay 60 min after LPS stimulation. As shown in Figure 3B -i and ii, the activity levels of the NFB p50 and p65 subunits were suppressed in tobramycin-treated NCI-H292 cells as compared to the LPS control cells. These results suggest that tobramycin influences p50 and p65 activity.
Inhibitors of MAP kinase and NFB block LPS-induced MUC5AC
production. To examine the cell signaling pathway of LPS via TLR4 in NCI-H292 cells, we performed an inhibition assay of the cell signaling pathway. As shown in Figure 4 , the NFB inhibitor CAPE, the ERK inhibitor PD98059, the p38 MAP kinase inhibitor SB203580, and the JNK inhibitor SP600125 effectively suppressed the MUC5AC protein production compared with the LPS control cells. These results indicate that LPS from P. aeruginosa influences MUC5AC production via the MAPK pathway.
High-dose tobramycin inhibits the phosphorylation of MAP kinase in
LPS-activated NCI-H292 cells.
To examine a potential role for the signaling molecules upstream of NFB, we examined the phosphorylation of kinase, which is the extracellular signaling pathway of TLR4. Lysates of LPS-treated NCI-H292 15 cells were subjected to western blotting. As shown in Figure 5 , ERK and p38 MAP kinase were phosphorylated in the LPS control cells and the phosphorylation of ERK, and p38 MAP kinase suppressed in tobramycin-treated cells. These results support the possibility that the inhibition of the phosphorylation of MAP kinase by tobramycin contributes to the suppression of MUC5AC. that up-regulates transcription of the mucin genes (Li et al., 1997) , and LPS is present in the supernatant and can activate MUC5AC (Dohrman et al., 1998) .
Discussion
In cystic fibrosis patients, P. aeruginosa has been found to grow to high concentrations with biofilm and intravenous antibiotics can't reach the appropriate concentration to the infectious source (Singh et al., 2000) , therefore, it is difficult to eradicate this organism 
